网站首页
请拖入内容到容器
对于咱们
请拖入内容到容器
华讯
Huawei and Verizon, patent litigation to reconciliation
Huawei and Verizon, patent litigation to reconciliation Huawei and Verizon Communications have agreed to settle two lawsuits alleging patent infringement, it was reported on July 12, Beijing time. Over the past 20 years, Huawei has reportedly conducted extensive cross-licensing negotiations with major patent holders in the telecom industry, and has signed more than 100 patent licensing agreements with major ICT manufacturers in the United States, Europe, Japan and South Korea. Together of the two separate cases, already in Texas last week trial. But late on Sunday local time, Huawei and Verizon filed joint motions in two US courts to dismiss both cases, as well as Verizon's counterclaim. In February 2020, Huawei sued Verizon, accusing the company of unauthorized use of more than a dozen Huawei patents in computer networks, download security, and video communications, seeking damages and royalties. In response to today's settlement, Huawei said in a statement: "We are pleased that the two companies have reached a settlement that ends their patent litigation. The terms of the agreement are confidential." People familiar with the matter said huawei's claims could exceed $1 billion. Huawei also noted that it has "more than 100,000 patents in force worldwide, including approximately 10,000 in the United States." Verizon has yet to comment, but said last year that the lawsuits were little more than a public relations stunt. In addition, Verizon has countersued Huawei for patent infringement. "We simply ask Verizon to respect Huawei's investment in research and development and either pay for the use of our patents or refrain from using them," Huawei said last year. Since 2015, huawei won the intellectual property rights of income accumulative total more than $1.4 billion, history accumulated more than 6 billion dollars to pay royalties for legitimate use other company's patent, with 80% paid to American companies. Only high investment can bring high return. The technology that leads the world is huawei's money. Billions and billions of research and development of a technology, with what provided free of charge to each other. So the royalty fees charged by huawei won't give up, how many patent verizon specific to huawei is unknown, but can be seen from the attitude of tough royalties huawei, technology is the absolute principle. With technology, we can promote the development of science and technology, and with technology, we are not afraid of intransigence. Huawei will insist on research and development, more technical breakthrough, form a larger system of patented technology.
Details 白箭头 黑箭头
华讯受邀列席2021第一届天下大师长教师芯片设想暑期黉舍开班典礼
7月12日,华讯受邀参与2021第一届天下大师长教师芯片设想暑期黉舍开班典礼。本次勾当在树模性微电子学院产学融会成长同盟的指点下,由北京大学国度集成电路产教融会立异平台、西北大学微电子学院、南京集成电路培训基田主理,南京集成电路培训基地集成电路培训基地集成电路设想培训部、中科院微电子所南京智能手艺钻研院包办,同时,也取得了华讯、创意电子等多家企业的撑持。 西北大学首席传授、南京集成电路培训基田主任时龙兴,江北新区研创园党工委副布告、南京集成电路培训基地布告周荣,北京大学微纳电子学钻研院副院长贾嵩,西北大学电子迷信与工程学院副院长徐申及相干企业代表参与,南京华讯常识产权参谋无限公司总司理侯庆辰师长教师也受邀参与本次勾当。 勾当上,各大高校教员对这次芯片暑期黉舍的创办颁发了发言:暑期黉舍是在国度计谋下,经由过程处所当局、高校、企业等多方配合尽力培育集成电路设想人材的一个别现。但愿列位同窗在暑期黉舍有所收成,在将来可以或许成为财产成长的中坚气力。 芯片设想人材是我国集成电路财产高品质成长的焦点身分之一。IC设想财产的扶植成长离不开优异人材的支持,南京集成电路培训基地举行首届天下大师长教师芯片设想暑期黉舍,约请产学界的行业手艺专家、高程度传授,环绕行业热门、智能芯片设想主题展开钻研课程、讲座、名目指点、行业精英面临面交换,将行业热门手艺及实在名目相连系,以钻研课程与名目理论为手腕,并支配芯片设想范畴相干手艺及东西的培训,首要培育立异型的IC设想人材。 华讯在芯片行业常识产权范畴一向有着最专业常识和技术,为多家芯片企业的立异专利助力。这次芯片设想暑期黉舍的创办,华讯也会尽最大尽力为师长教师供给赞助,为增进中国芯片财产成长出一份力。
Details 白箭头 黑箭头
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes This month FDA announced that they have approved Kerendia (finerenone) tablets for the treatment of patients with chronic kidney disease associated with type 2 diabetes. Kerendia is indicated to delay chronic kidney disease progression. It is able to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adult diabetic patients. Now the drug has also been submitted for marketing authorization in China, European Union and other countries. There are 422 million people with diabetes, and there are up to 40% of all patients with type 2 diabetes develop chronic kidney disease. Diabetes is one of the most common causes of chronic kidney disease and kidney failure. Chronic kidney disease is the gradual loss of kidney function over a period of months to years. It occurs when the kidneys are damaged and cannot filter blood normally, and sometimes can progress to kidney failure. The patients are also at high risk of heart disease because of defective filtering. Kerendia is the first and only nonsteroidal mineralocorticoid receptor antagonist (MRA) for Type 2 diabetic patients with chronic kidney disease, compared to SGLT2 inhibitors, Farxiga (dapagliflozin) and Invokana (canagliflozin). It blocks overactivation of the mineralocorticoid receptor (MR) which contributes to fibrosis and inflammation. The drug is able to target fibrosis and inflammation to slow kidney disease progression. The efficacy of Kerendia was evaluated in a randomized, multicenter, double-blind, placebo-controlled in the phase III trial. There were 5,674 patients in the study. The study found that Kerendia beat placebo when it came to kidney function. That included fending off or slowing progression to kidney failure and kidney death. Furthermore, the study also found that Kerendia reduced the risk of cardiovascular death, non-fatal heart attack, and hospitalization for heart failure.   Kerendia received priority review and fast track designations for their application, and it will be commercially available in the U.S. by the end of July.   資料來源: http://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease http://www.pharmalive.com/bayers-kerendia-receives-u-s-fda-approval/ http://finance.yahoo.com/news/bayers-kerendia-scores-long-awaited-111105329.html http://www.businesswire.com/news/home/20210709005441/en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-U.S.-FDA-Approval-for-Treatment-of-Patients-with-Chronic-Kidney-Disease-Associated-with-Type-2-Diabetes http://www.healio.com/news/endocrinology/20200710/finerenone-delays-diabetic-kidney-disease-progression-fideliodkd  
Details 白箭头 黑箭头
最新动静
请拖入内容到容器
首要办事
请拖入内容到容器
华讯
华讯
华讯

德律风:+86 25 56673162

地点:江苏省南京市江北新区江淼路88号起飞大厦B座20层2001

版权一切 © 南京华讯常识产权参谋无限公司      备案号:      网站扶植:        

接洽咱们
请拖入内容到容器
网站首页
对于咱们
最新动静
首要办事
接洽咱们